Gilead $GILD is down on the day after the company reported sharply lower top-line earnings. Why is the market so disappointed?Kite acquisition costs are baked in. Per notes from user @BioNoob, Investors knew the HCV market was declining. Abbvie's $ABBV Mavyret came in significantly lower priced and would capture more of the market share. This is should have been baked into any consideration buy Gilead or it's future. There's going to be very little news from a pipeline perspective for next year. If in 60s or lower, would be a great entry point. They're growth will be dependent upon HIV and especially gene therapy. It's too early to speculate on the NASH pipeline. Gilead needs to nail the gene therapy part down; otherwise, there will be continued stock pressure. Once Gilead and other gene therapy companies resolve current reimbursement hurdles with CMS, this would be a great dividend growth company again.GILD stock intra-day (May 2): $GILD, Gilead Sciences, Inc. / H1 Buy Gilead Sciences in the $60's. Agree or disagree?